Citation: Athauda D et al., 2025, New England Journal of Medicine, DOI 10.1056/NEJMoa2306791Research Summary:A randomized double-blind Phase 2 trial evaluated lixisenatide, a GLP-1 receptor agonist, in 156 individuals Participants received lixisenatide or placebo over 12 months. The lixisenatide group maintained stable with a decline in the placebo group. Gastrointestinal effects …
Read More »
Team Science for Dementia: The ADRC Circular Loop (Discovery → Development → Delivery → Dissemination) Harnessing Team Science in Dementia Research: The ADRC Circular Loop Citation: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Curator: Warren Peters, MD MPH FOMA • Silo: Voice …
Read More »
Cognitive health during aging is not just about genes or willpower. It’s about where we’re born, live, learn, work, and age—the social determinants of health (SDOH)—and the policies that shape those conditions. Because social environments and access to resources differ widely, not everyone experiences healthy cognitive aging. This long-form guide …
Read More »
Overview Parkinson’s shows up differently for everyone. This quick read answers the five questions families ask first, with links you can use today. Keep it simple, repeatable, and share what you’re seeing with your care team. Subscribe 1) Early signs? Tremor at rest, slowed movement, stiffness, small handwriting, and softer …
Read More »
Pfizer’s Strategic Deal with the Trump Administration: A Masterstroke in Corporate Diplomacy In a move that has sent ripples through the pharmaceutical and political landscapes, Pfizer has announced a landmark agreement with the Trump administration to lower drug prices and invest heavily in domestic manufacturing. This three-year agreement, which runs …
Read More »
Introduction: Shifting the Paradigm in Alzheimer’s Research The landscape of Alzheimer’s disease (AD) research is undergoing a significant transformation. For decades, the focus has been on the amyloid hypothesis, with a multitude of clinical trials targeting amyloid-beta plaques, often with disappointing results. However, recent developments, including the NIA’s strategic funding …
Read More »Executive Summary Gait variability—particularly stride-time variability (STV) and stride-length variability—has emerged as a promising but context-dependent digital signal for Parkinson’s disease (PD). Across recent studies, STV is repeatedly sensitive to disease state and intervention effects, yet its interpretability hinges on speed control, environment (overground vs treadmill), fatigue, footwear, and surface. …
Read More »
promptsyndicate.ai GenAI-powered platform built for a 2030 world — where smartphones are the new printing press